Tilray: Same Tired Story
Tilray reported misleading revenue growth in FQ4 due to not comparing pro-forma revenue from the merger for the quarter. The Canadian cannabis company is still struggling to grow due to lockdowns in Canada and Germany. The stock trades at substantial premium P/S multiple while risks exist on a U.S. acquisition plan. Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our model portfolio. Learn More » Before the market open, Tilray ( TLRY ) reported FQ4 results to provide the first quarterly results of the combined Aphria and Tilray operations. Unfortunately, the Canadian cannabis company failed to provide pro-forma numbers for the combination. My investment thesis remains Bearish on the stock after the 20% rally in early trading. Read the full article on Seeking Alpha. Disclosure: No position mentioned. Please review the disclaimer page for more details. Update - Jul...